Yinghui Guan

Correction to: Nature https://doi.org/10.1038/s41586-026-10718-x Published online 1 July 2026 In the version of this article initially published, the name of Jaime Merchán was misspelled (Jamie Merchan) and is now amended in the HTML and PDF versions of the article.

Abstract Clear cell renal cell carcinoma (ccRCC) is largely driven by the transcription factor hypoxia-inducible factor 2α (HIF-2α)1. Here we show that monotherapy with casdatifan—an orally bioavailable, potent and selective HIF-2α inhibitor2—produces meaningful, durable antitumour activity with manageable safety in individuals with refractory metastatic ccRCC.

Keywords HCC molecular subtype liver cell lineages atezolizumab bevacizumab immunotherapy mechanisms of response and resistance Introduction Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide and the fourth most lethal.1 Combination immunotherapy with atezolizumab and bevacizumab has become a new standard of care as the first-line therapy for unresectable HCC by demonstrating strong antitumor activity in an initial phase 1b study (GO30140)2 and subsequently superior...